放射性^(125)I粒子联合化疗治疗晚期非小细胞肺癌的临床研究  

Clinical Value of CT-guided Radioactive Seeds 125I Implantation Combined With GP Regimen Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：蒲德利[1] 张福君[2] 廖江荣[1] 陈栋[2] 韩建军[2] 李传行[2] 

机构地区：[1]贵州航天医院肿瘤治疗中心,贵州563003 [2]中山大学肿瘤医院影像介入中心,广东510060

出　　处：《当代医学》2010年第23期450-452,共3页Contemporary Medicine

摘　　要：目的探讨CT引导下125I粒子植入联合吉西他滨、顺铂(GP方案)化疗治疗晚期非小细胞肺癌的临床价值。方法 26例非小细胞肺癌患者(Ⅲa～Ⅳ期),均先行吉西他滨联合顺铂静脉化疗2～3个周期,再行125I放射性粒子植入术,术前采用TPS治疗计划系统算出术中所需125I粒子数量、粒子分布情况、进针方向。在螺旋CT导向下将125I放射性粒子植入肿瘤实质内及肿瘤边缘。结果 26例患者中,完全缓解(CR)21例,部分缓解(PR)4例,稳定(NC)1例,进展(PD)0例。中位生存期14月,1年生存率76.92%。所有患者未出现放射损伤症状,未发现粒子迁移,有化疗不良反应(Ⅰ～Ⅳ度急性骨髓抑制,Ⅰ～Ⅲ度恶心呕吐,少量脱发)。结论放射性125I粒子植入联合联合化疗治疗非小细胞肺癌是安全有效的,具有一定临床应用价值。Objective To evaluate clinical effi cacy of CT-guided radioactive seeds 125I implantation combined with GP regimen（gemcitabine plus cisplatinum） chemotherapy in the treatment of advanced non-small cell lung cancer（NSCLC） . Methods Twenty-six patients with NSCLC（Ⅲa ～Ⅳstage） received venous GP regimen chemotherapy for two three periods at fi rst. CT-guided radioactive seeds 125I implantation was accepted and verifi ed according to treatment planning system（TPS） . Results Among 26 patients,CR was 21,PR was 8,NC was 1,PD was 0. Median survival time was 14 months and one year survival rate achieved 73.08%. All patients without symptoms that radiation injury,seeds migration,chemotherapy adverse reaction（Ⅰ～Ⅳacute myelosuppression,Ⅰ～Ⅲgastrointestinal reaction,mild trichomadesis） . Conclusions CT-guided radioactive seeds 125I implantation combined with GP regimen chemotherapy in the treatment of advanced non-small cell lung cancer is safe and effective,proves a certain clinical application value.

关 键 词：非小细胞肺癌 介入治疗 化疗 放射性125I粒子 

分 类 号：R734.2[医药卫生—肿瘤]